Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

US Patent 11926672 · Granted Mar 12, 2024

Estimated economic value: $372,313,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Anti-ASGR-1 monoclonal inhibitory antibodies2025
Interleukin-21 mutein/ anti-PD-1 antibody conjugates2023
Anti-PD-1 antibodies and methods of treatment2022
Compositions and methods for the treatment of immune related diseases2022
Hydrazone derivatives for the treatment of cancer2020
Zinc complexes of hydrazones and (thio)semicarbazones and their use for the trea2020
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibit2020
Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibit2020
(Thio, oxo, and seleno) semicarbazone derivatives and their use for treating can2020
(Thio, oxo and seleno) semicarbazone complexes with zinc and their use for treat2020
(Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for trea2019
Method of reducing blood glucose by administering RON agonists2018